Nutex Health Inc.

Listed Company

NUTXCIK 0001479681NasdaqAcceleratedServices-Business Services, NecDelawareFY ends Dec 31

Period

FY 2025

Revenue

$875.26M

Net Income

$70.79M

Total Assets

$918.52M

Equity

$329.45M

Shares Out

6.88M

Op. Cash Flow

$248.13M

Business

Nutex Health, Inc. is a physician-led healthcare services and operations company that develops, owns, and manages micro-hospitals and population health networks. It provides comprehensive 24/7 clinical services including emergency care, inpatient and behavioral health, onsite imaging, certified laboratories, inpatient pharmacies, and management services for independent physician associations and physician groups. The company reports operations across three segments: a hospital division, a population health management division (including an MSO and IPAs), and a real estate division that owns and leases facility properties. Nutex distributes services across multiple U.S. states through micro-hospitals, HOPDs, IPAs, and centralized administrative support to payors and patients.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	875	480	248	219	332
Payroll	158	118	108	112	94
Contract services	190	101	42	36	17
Medical supplies	17	15	14	12	13
Depreciation and amortization	21	19	18	—	—
Other	45	31	30	31	21
Total operating costs and expenses	431	284	213	204	152
Gross profit	444	196	35	15	179
Facilities closing costs	0	0	217,000	—	—
Acquisition costs	0	0	44,000	4	4
Stock-based compensation	117	17	3	189,581	—
Impairment of assets	0	4	29	—	—
Impairment of goodwill	0	3	1	—	0
General and administrative expenses	52	42	33	20	5
Total corporate and other costs	169	66	67	422	9
Operating income (loss)	276	131	−32	−407	170
Interest expense, net	22	20	16	12	—
Loss on warrant liability	0	2	0	—	—
Other (income) expense	9	−669,000	399,000	559,299	−5
Income (loss) before taxes	245	110	−48	−420	169
Income tax expense (benefit)	64	15	−5	13	965,731
Net income (loss)	180	95	−43	−433	169
Less: net income attributable to noncontrolling interests	110	43	2	−8	36
Net income (loss) attributable to Nutex Health Inc.	71	52	−46	−425	133
Basic earnings (loss) per common share (in dollars per share)	11.13	10.23	−10.39	−100.36	0.22
Diluted earnings (loss) per common share (in dollars per share)	10.48	9.69	−10.39	−100.36	0.22

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	186	41	22	34	36
Restricted cash	297,000	0	—	—	—
Restricted short-term investments	0	3	—	—	—
Accounts receivable	—	232	59	58	113
Inventories	3	3	3	4	3
Prepaid expenses and other current assets	25	10	3	2	323,283
Total current assets	539	292	91	98	154
Property and equipment, net	95	78	81	82	152
Operating lease right-of-use assets	27	28	12	20	22
Financing lease right-of-use assets	222	219	176	193	65
Intangible assets, net	21	16	21	21	682,649
Goodwill, net	14	14	17	17	1
Deferred tax assets	0	8	—	—	—
Other assets	662,000	711,000	—	—	—
Total assets	919	655	398	432	395
Lines of credit	740,000	4	3	3	72,055
Current portion of long-term debt	13	14	11	13	—
Operating lease liabilities, current portion	2	2	2	2	1
Financing lease liabilities, current portion	7	8	4	4	1
Accrued arbitration expenses	50	48	—	—	—
Accrued income tax expense	867,000	27	—	—	—
Accrued stock-based compensation	8	16	—	—	—
Accrued expenses and other current liabilities	27	25	—	—	—
Total current liabilities	158	154	58	55	38
Long-term debt, net	29	22	26	23	79
Non-current operating lease liabilities, net	30	31	15	19	21
Non-current financing lease liabilities, net	269	259	214	204	66
Deferred tax liabilities	9	0	5	10	—
Total liabilities	495	467	319	311	203
Commitments and contingencies (Note 10)	—	—	—	—	—
Common stock, $0.001 par value; 950,000,000 shares authorized; 0 and 5,511,452 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	7,000	6,000	4,511	4,335	3,952
Additional paid-in capital	616	489	471	459	12
Accumulated deficit	−286	−357	−409	−363	102
Nutex Health Inc. equity	329	132	61	96	115
Noncontrolling interests	94	56	18	24	77
Total equity	423	189	79	120	192
Total liabilities and equity	919	655	398	432	395

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Derecognition of goodwill	0	453,000	0	—	—
Changes to deferred taxes	17	−13	−6	5	−984,810
Debt accretion expense	902,000	1	1	2	50,273
Loss on lease termination	0	0	58,000	—	−109,494
(Increase)/Decrease in Inventories	−16,000	540,000	143,000	−719,107	−1
(Increase)/Decrease in Prepaid expenses and other current assets	−15	−7	−817,000	−1	−233,114
(Increase)/Decrease in Operating right-of-use assets	917,000	1	2	—	—
Increase/(Decrease) in Operating lease liabilities	−508,000	−2	−2	—	—
Increase/(Decrease) in Accrued arbitration expenses	2	48	0	—	—
Increase/(Decrease) in Accrued income tax expense	−26	27	0	—	—
Increase/(Decrease) in Accrued expenses and other current liabilities	2	12	6	−1	4
Net cash provided by operating activities	248	23	1	51	173
Acquisitions of property and equipment	−3	−2	−9	—	—
Purchase of restricted short-term investment	0	−3	0	—	—
Cash related to sale of business	0	−361,000	0	—	—
Proceeds from restricted short-term investment	2	0	0	—	—
Payments for acquisitions of businesses, net of cash acquired	0	0	−704,000	—	—
Cash related to asset acquisition	−4	0	0	—	—
Cash related to deconsolidation of Real Estate Entities	0	0	−1	—	—
Net cash used in investing activities	−5	−6	−11	−4	−37
Proceeds from lines of credit	5	2	2	3	—
Proceeds from notes payable	0	7	17	815,881	20
Proceeds from convertible notes	0	0	5	—	413,917
Repayments of lines of credit	−8	−2	−2	−72,055	−864,659
Repayments of notes payable	−11	−10	−16	−7	−21
Repayments of finance leases	−5	−5	−3	—	—
Proceeds from common stock issuance, net issuance costs	0	9	0	—	—
Proceeds from exercise of warrants	0	2	0	4	153,424
Cash related to stock repurchases and retirements	−5	0	0	—	—
Members' contributions	767,000	3	298,000	—	—
Members' distributions	−74	−6	−5	—	—
Net cash provided by (used in) financing activities	−98	1	−2	−48	−126
Net change in cash and cash equivalents	145	19	−12	−2	11

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro